Cardiorenal multimorbidity in hospitalized cardiology patients: The Hellenic Cardiorenal Morbidity Snapshot (HECMOS)

Ioannis Leontsinis1, Dimitrios Farmakis2, Dimitrios Avramidis3

  • 1First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Greece.

Insights

The Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study found a high burden of cardio-reno-metabolic disease in Greek inpatients. Heart failure and atrial fibrillation were the most common co-occurring conditions.

Area of Science:

  • Cardiology
  • Nephrology
  • Internal Medicine

Background:

  • Cardiovascular disease frequently coexists with renal dysfunction.
  • Multimorbidity significantly impacts patient prognosis and hospital stay duration.
  • Understanding the contemporary burden of cardiorenal disease is crucial for healthcare planning.

Purpose of the Study:

  • To assess the current prevalence and patterns of cardiorenal morbidity among hospitalized cardiology patients in Greece.
  • To identify the most common co-morbidities within the cardiorenal nexus.
  • To provide a national snapshot of cardio-reno-metabolic disease burden.

Main Methods:

  • The Hellenic Cardiorenal Morbidity Snapshot (HECMOS) utilized an electronic platform for data collection.
  • Data were gathered on a single day (March 3, 2022) across diverse inpatient cardiology settings in Greece.
  • The study aimed for a real-world, nation-representative sample covering various healthcare levels and territories.

Main Results:

  • A total of 923 patients were included, with a median age of 73 years; 68.4% were male.
  • Hypertension (66%), chronic heart failure (38%), diabetes mellitus (31.8%), atrial fibrillation (30%), and chronic kidney disease (26%) were highly prevalent.
  • 64.1% of patients had at least one of these four conditions, with heart failure and atrial fibrillation being the most frequent combination (20.6%).

Conclusions:

  • Participants in the HECMOS study exhibited a substantial burden of cardio-reno-metabolic diseases.
  • The co-occurrence of heart failure and atrial fibrillation represents the most prevalent cardiorenal comorbidity pattern observed.
  • Findings highlight the significant challenge posed by multimorbidity in inpatient cardiology care in Greece.
Abstract

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
20
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
13
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
13
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
18
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
29
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474